Description
Ibrance is an exclusively branded prescription medication; presently, no generic equivalent exists. It serves adults with advanced breast cancer, specifically:
- Cancer that has spread or is advanced/metastatic.
- Hormone receptor-positive cancer (stimulated by estrogen/progesterone).
- HER2-negative cancer (normal HER2 protein levels).
Ibrance, alongside specific hormone therapies, is prescribed. Hormone therapy curbs estrogen’s cancer-stimulating effects.
Both genders can use Ibrance in specific cases.
Ibrance’s active ingredient is Palbociclib. Administered orally through capsules or tablets, it comes in three strengths: 75mg, 100mg, and 125mg.
Ibrance is a targeted therapy for this type of breast cancer, slowing and targeting the growth of cancer cells, which otherwise multiply uncontrollably.